CY1108629T1 - Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου - Google Patents

Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου

Info

Publication number
CY1108629T1
CY1108629T1 CY20081101393T CY081101393T CY1108629T1 CY 1108629 T1 CY1108629 T1 CY 1108629T1 CY 20081101393 T CY20081101393 T CY 20081101393T CY 081101393 T CY081101393 T CY 081101393T CY 1108629 T1 CY1108629 T1 CY 1108629T1
Authority
CY
Cyprus
Prior art keywords
combination
fluorouracil
medicines
heart
therapeutic treatment
Prior art date
Application number
CY20081101393T
Other languages
English (en)
Inventor
Mary Ellen Rybak
Original Assignee
Pharma Mar, S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar, S.A.U. filed Critical Pharma Mar, S.A.U.
Publication of CY1108629T1 publication Critical patent/CY1108629T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Δίδονται μεθόδοι δια την θεραπευτική αγωγή καρκίνου εις ανθρώπινο σώμα. Σε μορφή πραγματοποιήσεως θεραπευτική ποσότης καπεσιταβίνης χορηγείται σε συνδυασμό με ΕΤ 743 σε περιοχή δόσεων μεταξύ 0,75 mg/m2 και 1,4 mg/m2 δια το ΕΤ 743. Σε σχετική μορφή πραγματοποιήσεως, αποτελεσματική θεραπευτική ποσότης ΕΤ 743 χορηγείται σε συνδυασμό με καπεσιταβίνη σε περιοχή δόσεων μεταξύ 1.500 mg/m2 / ημέρα και 2.500 mg/m2 / ημέρα δια την καπεσιταβίνη.
CY20081101393T 2003-11-13 2008-12-02 Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου CY1108629T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51969003P 2003-11-13 2003-11-13
EP04798717A EP1689404B9 (en) 2003-11-13 2004-11-15 Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1108629T1 true CY1108629T1 (el) 2014-04-09

Family

ID=34619369

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101393T CY1108629T1 (el) 2003-11-13 2008-12-02 Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου

Country Status (15)

Country Link
US (1) US7622458B2 (el)
EP (1) EP1689404B9 (el)
JP (1) JP2007511499A (el)
AT (1) ATE406897T1 (el)
CA (1) CA2544320A1 (el)
CY (1) CY1108629T1 (el)
DE (1) DE602004016376D1 (el)
DK (1) DK1689404T3 (el)
ES (1) ES2314470T3 (el)
HR (1) HRP20080598T3 (el)
PL (1) PL1689404T3 (el)
PT (1) PT1689404E (el)
RS (1) RS50692B (el)
SI (1) SI1689404T1 (el)
WO (1) WO2005049031A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
NZ525730A (en) * 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
PL1658848T3 (pl) * 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd
US20080292729A1 (en) * 2005-07-21 2008-11-27 Nuvo Research Inc. Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP2786755A3 (en) * 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
JP7303205B2 (ja) * 2018-02-12 2023-07-04 アレイ・バイオファーマ・インコーポレーテッド 胆道癌を処置するための方法および併用療法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CA2327468C (en) 1998-04-06 2008-05-06 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
US6316214B1 (en) 1998-05-11 2001-11-13 The Board Of Trustees Of The University Of Illinois ETM-775 metabolite of ecteinascidin 743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
CZ298259B6 (cs) * 2000-02-28 2007-08-08 Aventis Pharma S. A. Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
EP1356097A2 (en) 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
NZ525730A (en) 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
BR0213424A (pt) 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
AU2004291037A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
CN101119750B (zh) 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
PL1658848T3 (pl) 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd

Also Published As

Publication number Publication date
ES2314470T3 (es) 2009-03-16
EP1689404A1 (en) 2006-08-16
JP2007511499A (ja) 2007-05-10
PT1689404E (pt) 2008-12-15
CA2544320A1 (en) 2005-06-02
EP1689404B1 (en) 2008-09-03
ATE406897T1 (de) 2008-09-15
DE602004016376D1 (de) 2008-10-16
DK1689404T3 (da) 2009-01-26
EP1689404B9 (en) 2009-04-22
SI1689404T1 (sl) 2009-02-28
RS50692B (sr) 2010-06-30
US7622458B2 (en) 2009-11-24
US20070190164A1 (en) 2007-08-16
WO2005049031A1 (en) 2005-06-02
HRP20080598T3 (en) 2009-01-31
PL1689404T3 (pl) 2009-02-27

Similar Documents

Publication Publication Date Title
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
NZ544472A (en) Compounds and therapeutical use thereof
NO20032027D0 (no) Effektive antitumorbehandlinger
NO20072543L (no) Anti-cancer-behandling
HK1071310A1 (en) Combination therapy for the treatment of cancer
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
JP2006500346A5 (el)
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
ATE339209T1 (de) Kombinationstherapie mit gemzitabin und zd6126
UA3976U (uk) Спосіб лікування місцевопоширеного нерезектабельного раку прямої кишки
UA11290U (uk) Спосіб профілактики антрациклінового ушкодження серця
RU2002106480A (ru) Способ лечения запущенных форм злокачественных опухолей
BRPI0407301A (pt) Uso de uma combinação, composição farmacêutica, kit, e, método para o tratamento de câncer em um animal de sangue quente tal como um ser humano